Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Gabapentin Market, by Application
1.4.2 North America Gabapentin Market, by Dosage Form
1.4.3 North America Gabapentin Market, by Distribution Channel
1.4.4 North America Gabapentin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Gabapentin Market by Application
3.1 North America Epilepsy Market by Country
3.2 North America Restless Legs Syndrome Market by Country
3.3 North America Neuropathic Pain Market by Country
3.4 North America Others Market by Country
Chapter 4. North America Gabapentin Market by Dosage Form
4.1 North America Capsule Market by Country
4.2 North America Tablet Market by Country
4.3 North America Oral Solution Market by Country
Chapter 5. North America Gabapentin Market by Distribution Channel
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Retail Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Gabapentin Market by Country
6.1 US Gabapentin Market
6.1.1 US Gabapentin Market by Application
6.1.2 US Gabapentin Market by Dosage Form
6.1.3 US Gabapentin Market by Distribution Channel
6.2 Canada Gabapentin Market
6.2.1 Canada Gabapentin Market by Application
6.2.2 Canada Gabapentin Market by Dosage Form
6.2.3 Canada Gabapentin Market by Distribution Channel
6.3 Mexico Gabapentin Market
6.3.1 Mexico Gabapentin Market by Application
6.3.2 Mexico Gabapentin Market by Dosage Form
6.3.3 Mexico Gabapentin Market by Distribution Channel
6.4 Rest of North America Gabapentin Market
6.4.1 Rest of North America Gabapentin Market by Application
6.4.2 Rest of North America Gabapentin Market by Dosage Form
6.4.3 Rest of North America Gabapentin Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Zydus Lifesciences Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Trials and approvals:
7.2 Glenmark Pharmaceuticals Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.4 Sun Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and Mergers:
7.5 Alkem Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Aurobindo Pharma Limited
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Cipla Limited
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Apotex, Inc.
7.10.1 Company Overview
Unique Offerings 